Giá của Noxopharm Limited là bao nhiêu (NOX)

Giá của Noxopharm Limited (NOX) là $0.04443294

Mũ thị trường của Noxopharm Limited là gì (NOX)

Giới hạn thị trường của Noxopharm Limited (NOX) là $13.65M

Thu nhập Noxopharm Limited (NOX)

Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers. Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors. The LuPIN program explores a combined therapy of Veyonda and 177Lu-PSMA-617 for advanced prostate cancer. The IONIC program combines Veyonda with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, targeting various solid tumor types. Its Chemotherapy Enhancement Program (CEP) integrates Veyonda with carboplatin for patients suffering from refractory solid tumors in areas such as the breast, head and neck, lung, prostate, and ovaries. Furthermore, the NOXCOVID Program is conducting a dose escalation and expansion study of NOX66 for the treatment of COVID-19 infection. The company is also investigating potential treatments for pancreatic cancer and glioblastoma. Noxopharm collaborates with the Hudson Institute of Medical Research and The Australian National University on the research and development of therapeutic drugs for inflammatory disorders. Incorporated in 2015, the company's operations are based in Chatswood, Australia.

Năm	Thu nhập	Thay đổi
2026 (TTM)	$-4.15M	29.05%
2025	$-3.22M	-19.45%
2024	$-3.99M	-71.53%
2023	$-14.02M	-15.43%
2022	$-16.58M	136.55%
2021	$-7.01M	23.32%
2020	$-5.68M	-50.43%
2019	$-11.46M	-19.51%
2018	$-14.24M	507.24%
2017	$-2.35M	334.19%
2016	$-540.21K	0.00%

Năm

Thu nhập

Thay đổi

2026 (TTM)

$-4.15M

29.05%

2025

$-3.22M

-19.45%

2024

$-3.99M

-71.53%

2023

$-14.02M

-15.43%

2022

$-16.58M

136.55%

2021

$-7.01M

23.32%

2020

$-5.68M

-50.43%

2019

$-11.46M

-19.51%

2018

$-14.24M

507.24%

2017

$-2.35M

334.19%

2016

$-540.21K

0.00%

Công ty	Thu nhập	Chênh lệch thu nhập	Quốc gia
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-127,225.42%	US
Moderna, Inc. MRNA.US	$-3.09B	74,296.89%	US
CSL Limited CSL.AX	$-4.02B	96,690.59%	AU
Argenx SE ARGX.US	$1.95B	-47,110.79%	NL
Lonza Group AG LONN.SW	-	-	CH

Công ty

Thu nhập

Chênh lệch thu nhập

Quốc gia